In Brief: Bristol-Myers Squibb Maxipime
Executive Summary
Bristol-Myers Squibb Maxipime: Cefepime approved for supplemental indication of monotherapy for empiric treatment of febrile neutropenic patients. Maxipime is the first antibiotic approved for the indication. Recommended dosing is two grams I.V. every eight hours for seven days or until resolution of neutropenia. NDA 50-679/SE1-002 was submitted May 17, 1996 and approved May 16...